Karmazyn M, Haist J V
Department of Pharmacology and Toxicology, University of Western Ontario, London, Canada.
Cardiovasc Res. 1993 Mar;27(3):390-5. doi: 10.1093/cvr/27.3.390.
The aim was to examine the cardiac effects of phorbol esters over a wide concentration range and to determine if the effects are related to Ca2+ availability.
Studies were carried out using isolated rat hearts exposed for 60 min either to phorbol 12-myristate 13-acetate (PMA, 10(-11) to 10(-6) M) or phorbol 12,13-dibutyrate (PDBu, 10(-12) to 10(-7) M) in the presence of either 1.25 or 2.50 mM CaCl2. Experiments were also done to assess the effect of BAY K8644, a Ca2+ agonist, on phorbol ester effects. After treatment, hearts were freeze clamped for later analysis of energy products.
At the lowest concentrations studied, both PMA and PDBu produced positive inotropic effects, whereas higher concentrations resulted in a loss of contractile force in hearts perfused with 1.25 mM CaCl2. Doubling the CaCl2 concentration or the presence of BAY K8644 had little effect on the negative inotropic influence of either phorbol ester but reversed the positive inotropic effect to a negative inotropic one. Neither treatment had any effect on the coronary constricting effects of phorbol esters. Increases in resting tension and reductions in high energy phosphate content were evident only with the highest phorbol ester concentrations and were unaffected either by changes in CaCl2 concentrations or the presence of BAY K8644.
At picomolar and nanomolar concentrations phorbol esters produce positive inotropic actions which are probably mediated by enhanced Ca2+ influx. Although higher concentrations produce negative inotropic effects, these are not influenced by [Ca2+]o nor are they related to disturbances in energy metabolism except at the highest concentrations. We conclude that phorbol esters produce complex concentration dependent cardiac effects which are not mediated by a single mechanism of action.
本研究旨在检测佛波酯在较宽浓度范围内对心脏的影响,并确定这些影响是否与钙离子的可利用性有关。
使用离体大鼠心脏进行实验,将心脏暴露于佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA,10⁻¹¹至10⁻⁶M)或佛波醇12,13-二丁酸酯(PDBu,10⁻¹²至10⁻⁷M)60分钟,同时分别加入1.25或2.50mM氯化钙。还进行了实验以评估钙离子激动剂BAY K8644对佛波酯作用的影响。处理后,将心脏冷冻钳夹,以备后续分析能量产物。
在研究的最低浓度下,PMA和PDBu均产生正性肌力作用,而较高浓度则导致灌注1.25mM氯化钙的心脏收缩力丧失。氯化钙浓度加倍或加入BAY K8644对两种佛波酯的负性肌力作用影响不大,但将正性肌力作用逆转成负性肌力作用。两种处理对佛波酯的冠状动脉收缩作用均无影响。仅在最高佛波酯浓度下,静息张力增加和高能磷酸盐含量降低才明显,且不受氯化钙浓度变化或BAY K8644存在的影响。
在皮摩尔和纳摩尔浓度下,佛波酯产生正性肌力作用,这可能是由增强的钙离子内流介导的。虽然较高浓度会产生负性肌力作用,但这些作用不受细胞外钙离子浓度影响,除了在最高浓度外,也与能量代谢紊乱无关。我们得出结论,佛波酯产生复杂的浓度依赖性心脏效应,其并非由单一作用机制介导。